| scholarly article | Q13442814 |
| P50 | author | Jie Xu | Q47095324 |
| P2093 | author name string | Ye Hu | |
| Jin Qian | |||
| Jing-Yuan Fang | |||
| Xiaolin Zhou | |||
| Haoyan Chen | |||
| Jilin Wang | |||
| P2860 | cites work | Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. | Q52561781 |
| Gain of function of mutant p53 by coaggregation with multiple tumor suppressors | Q57670523 | ||
| Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome | Q81166001 | ||
| Ionizing radiation induces a dramatic persistence of p53 protein accumulation and DNA damage signaling in mutant p53 zebrafish | Q85194197 | ||
| RhoGAPs attenuate cell proliferation by direct interaction with p53 tetramerization domain | Q39150487 | ||
| Colorectal cancer cells refractory to anti-VEGF treatment are vulnerable to glycolytic blockade due to persistent impairment of mitochondria | Q39191124 | ||
| Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. | Q39225768 | ||
| Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation. | Q45341269 | ||
| T antigen is bound to a host protein in SY40-transformed cells | Q29618321 | ||
| Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion | Q30537354 | ||
| Discovery analysis of TCGA data reveals association between germline genotype and survival in ovarian cancer patients | Q30612061 | ||
| Increased oxidative metabolism in the Li-Fraumeni syndrome | Q34008143 | ||
| Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 database | Q34631589 | ||
| p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53. | Q35227440 | ||
| Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53. | Q35804653 | ||
| Mutant p53: one name, many proteins | Q36070574 | ||
| Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis | Q36920797 | ||
| The impact of p53 in predicting clinical outcome of breast cancer patients with visceral metastasis | Q37031974 | ||
| Single nucleotide polymorphisms in the mitochondrial displacement loop and age-at-onset of renal cell carcinoma | Q37087053 | ||
| Requirement for phosphorylation of P53 at Ser312 in suppression of chemical carcinogenesis | Q37269994 | ||
| Zebularine inhibits tumorigenesis and stemness of colorectal cancer via p53-dependent endoplasmic reticulum stress. | Q37307220 | ||
| The tumor suppressor p53: from structures to drug discovery | Q37762069 | ||
| p53 mutations in cancer | Q38069463 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported | Q15643954 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Li-Fraumeni syndrome | Q187542 |
| heterogeneity | Q928498 | ||
| P304 | page(s) | 4223 | |
| P577 | publication date | 2014-02-27 | |
| P1433 | published in | Scientific Reports | Q2261792 |
| P1476 | title | Heterogeneity of Li-Fraumeni syndrome links to unequal gain-of-function effects of p53 mutations | |
| P478 | volume | 4 |
| Q55397197 | A protein folding molecular imaging biosensor monitors the effects of drugs that restore mutant p53 structure and its downstream function in glioblastoma cells. |
| Q47150811 | ActiveDriverDB: human disease mutations and genome variation in post-translational modification sites of proteins |
| Q42775929 | Allele-specific wild-type TP53 expression in the unaffected carrier parent of children with Li-Fraumeni syndrome |
| Q37722958 | Breast cancer in patients with Li-Fraumeni syndrome - a case-series study and review of literature. |
| Q51623974 | Cdkn2a suppresses metastasis in squamous cell carcinomas induced by the gain-of-function mutant p53(R172H). |
| Q91964954 | Do Mutations Turn p53 into an Oncogene? |
| Q33720157 | Elf3 drives β-catenin transactivation and associates with poor prognosis in colorectal cancer |
| Q53727895 | Evaluation of TP53 Pro72Arg and MDM2 SNP285-SNP309 polymorphisms in an Italian cohort of LFS suggestive patients lacking identifiable TP53 germline mutations. |
| Q28068551 | Gain of function of mutant p53: R282W on the peak? |
| Q36998156 | Gain-of-function miRNA signature by mutant p53 associates with poor cancer outcome |
| Q38705984 | Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations |
| Q47789753 | Insights into the Effect of the G245S Single Point Mutation on the Structure of p53 and the Binding of the Protein to DNA. |
| Q58736829 | Mutant TP53 G245C and R273H promote cellular malignancy in esophageal squamous cell carcinoma |
| Q47107350 | Mutant p53 partners in crime |
| Q38846785 | Oncogenic Mutant p53 Gain of Function Nourishes the Vicious Cycle of Tumor Development and Cancer Stem-Cell Formation |
| Q35717532 | Primed for cancer: Li Fraumeni Syndrome and the pre-cancerous niche |
| Q93001945 | Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma |
| Q48112435 | Proteomic identification of ERP29 as a key chemoresistant factor activated by the aggregating p53 mutant Arg282Trp |
| Q47833426 | Putting p53 in Context |
| Q36963387 | Radiation Sensitivity in a Preclinical Mouse Model of Medulloblastoma Relies on the Function of the Intrinsic Apoptotic Pathway |
| Q60300809 | Rare variant associated with Li-Fraumeni syndrome exhibits variable penetrance in a Saudi family |
| Q29615604 | Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma |
| Q48675160 | Successful Treatment of Recurrent Li-Fraumeni Syndrome-related Choroid Plexus Carcinoma |
| Q58792318 | Survival in males with glioma and gastric adenocarcinoma correlates with mutant p53 residual transcriptional activity |
| Q30377229 | Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers |
| Q88938409 | T-cell Responses to TP53 "Hotspot" Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers |
| Q34775855 | TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma. |
| Q64056701 | Targeting Oxidative Stress With Auranofin or Prima-1 to Circumvent p53 or Bax/Bak Deficiency in Myeloma Cells |
| Q92512528 | p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy |
Search more.